NASDAQ$TNYA
Tenaya Therapeutics Inc · Q3 2025 earnings
Q3 2025 earnings · · After market close · Investor relations
Briefing
Tenaya Therapeutics reported Q3 2025, revenue of $0.00, net loss of $26M.
For Q3 2025, Tenaya Therapeutics reported revenue of $0.00, a net loss of $26M. Management discusses operating trends, liquidity, and outlook in the quarterly filing.
- Revenue $0.00.
- Net loss $26M.
- Tenaya Therapeutics highlights liquidity, operations, and near-term priorities.
Headline financials
Revenue & EPS history
Tenaya Therapeutics · Revenue · Quarterly
$0
Forward guidance
The filing outlines Tenaya Therapeutics's outlook, including capital allocation, operating priorities, and sector risks relevant to upcoming periods.
Tailwinds
- Tenaya Therapeutics discusses operational execution and demand trends in the filing.
- Balance sheet and liquidity actions support the business plan.
- Pipeline milestones and partnerships are key catalysts.
- Cash runway supports R&D.
Headwinds
- Macro, pricing, and cost inflation may pressure margins.
- Segment mix and one-time items can affect comparability.
- Clinical and regulatory risk.
- Dilution and burn rate.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 17 quarterly earnings reports · overlaid with Q3 2025
+2.8%
Avg return
Earnings day
+2.1%
Avg return
5 days after
-5.6%
Avg return
30 days after
50%
9 / 18 earnings
Positive
+39.8%
Q3 2022
Best reaction
-18.7%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | +30.3% | -4.2% | |
| Q4 2025 | -1.3% | -0.2% | -19.7% | |
| Q3 2025 | -1.4% | -7.0% | -4.9% | |
| Q1 2025 | +7.8% | -3.3% | +38.2% | |
| Q4 2024 | -6.5% | -12.7% | -38.4% | |
| Q3 2024 | +17.4% | +20.7% | +68.1% | |
| Q1 2024 | -0.7% | +8.9% | -12.6% | |
| Q4 2023 | -8.9% | -5.1% | -13.6% | |
| Q3 2023 | -7.8% | -10.2% | -2.9% | |
| Q2 2023 | +7.3% | +0.0% | -24.6% | |
| Q1 2023 | +12.1% | +7.2% | +9.0% | |
| Q4 2022 | -18.7% | -20.6% | -25.9% | |
| Q3 2022 | +39.8% | +53.4% | +11.0% | |
| Q2 2022 | +1.5% | +6.5% | -11.3% | |
| Q1 2022 | -5.7% | -6.7% | -29.9% | |
| Q4 2021 | +6.0% | +3.2% | -5.0% | |
| Q3 2021 | +7.7% | -13.5% | -28.1% | |
| Q2 2021 | -2.8% | -12.6% | -6.5% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro